Venetoclax and hypomethylating agents in TP53 ‐mutated acute myeloid leukaemia-Reference-Cited by-同舟云学术

Venetoclax and hypomethylating agents in TP53 ‐mutated acute myeloid leukaemia

Published:2019-08-22 Issue:2 Volume:187 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Aldoss Ibrahim¹^ORCID,Zhang Jianying²,Pillai Raju³,Shouse Geoffrey¹,Sanchez James F.¹^ORCID,Mei Matthew¹,Nakamura Ryotaro¹,Stein Anthony S.¹,Forman Stephen J.¹,Marcucci Guido¹,Pullarkat Vinod¹

Affiliation:

1. Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research City of Hope Duarte CA USA

2. Department of Computational and Quantitative Medicine City of Hope Duarte CA USA

3. Department of Pathology City of Hope Duarte CA USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16166

Reference10 articles.

1. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

2. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

3. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

4. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

5. A novel hierarchical prognostic model of AML solely based on molecular mutations

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insights and therapeutic approaches in secondary AML;Frontiers in Oncology;2024-07-29

2. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment;Laboratory Medicine;2024-07-13

4. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia;Advances in Oncology;2024-05

5. Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia;JCI Insight;2024-04-22